Aflac Incorporated (AFLAC) - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Aflac Incorporated and subsidiaries for the period ended June 30, 2006. Aflac primarily sells supplemental health and life insurance in the United States and Japan. The company operates two main reportable segments: Aflac Japan and Aflac U.S. Results for interim periods are not necessarily indicative of full-year results.
Key Financial Metrics (Six Months Ended June 30, 2006)
| Metric | 2006 (In Millions) | 2005 (In Millions) |
|---|---|---|
| Total Revenues | $7,256 | $7,127 |
| Premiums | $6,098 | $6,061 |
| Net Investment Income | $1,066 | $1,033 |
| Realized Investment Gains | $64 | $15 |
| Net Earnings | $783 | $664 |
| Diluted EPS | $1.55 | $1.30 |
| Operating Cash Flow | $2,179 | $2,356 |
| Total Assets | $57,432 | $56,361 |
| Notes Payable (Debt) | $1,071 | $1,395 |
| Shareholders' Equity | $7,169 | $7,927 |
Profit Margins: The effective income tax rate was 34.7% for the six months ended June 30, 2006. Pretax operating earnings for the consolidated company were $1,131 million.
Material Changes vs. Prior Period
- Earnings Growth: Net earnings increased 17.9% to $783 million, driven by higher pretax operating earnings and increased realized investment gains ($64 million vs. $15 million).
- Investment Portfolio: Due to a rising interest rate environment, the company reported net unrealized losses on debt securities of $432 million at June 30, 2006, compared to net unrealized gains of $2.5 billion at December 31, 2005. This significantly reduced shareholders' equity.
- Debt Reduction: Notes payable decreased by $324 million to $1.071 billion, primarily due to the full repayment of 40 billion yen Samurai notes in June 2006.
- Segment Performance:
- Aflac Japan: Pretax operating earnings rose 8.9% to $857 million. Premium income was relatively flat in dollar terms but grew 6.5% in yen terms. New annualized premium sales declined 2.8% in yen terms due to weakness in the medical product category.
- Aflac U.S.: Pretax operating earnings increased 12.7% to $297 million. Premium income grew 9.7%, and new annualized premium sales rose 8.8%.
- Currency Impact: The yen strengthened against the dollar (115.24 at June 30, 2006, vs. 118.07 at Dec 31, 2005), increasing reported assets and liabilities by approximately $1.1 billion and $1.0 billion, respectively.
Guidance, Outlook, and Risks
- 2006 Guidance: Management's objective is to achieve net earnings per diluted share of at least $2.92, representing a 15.0% increase over 2005. This target excludes realized investment gains/losses and assumes no foreign currency translation impact.
- 2007 Outlook: The objective is to increase net earnings per diluted share by 15% to 16%.
- Sales Outlook: Aflac Japan sales are expected to be flat to down single digits for the remainder of 2006 due to crowded market conditions. Aflac U.S. sales are expected to grow 8% to 12% for the full year.
- Risks and Contingencies:
- Interest Rate Risk: A 100 basis point increase in interest rates could reduce the fair value of debt securities by approximately $4.9 billion.
- Currency Risk: Fluctuations in the yen/dollar exchange rate significantly impact reported results. The company uses cross-currency swaps and yen-denominated debt to hedge this exposure.
- Investment Credit Risk: The portfolio includes $1.042 billion in below-investment-grade securities (amortized cost), primarily Ahold, KLM, and Ford Motor Credit. No impairment charges were recognized in the period.
- Regulatory: Dividends from Aflac Japan are subject to Japanese Financial Services Agency (FSA) restrictions.
Investor Verification Checklist
- Unrealized Losses: Verify the company's assessment that the $432 million in net unrealized investment losses are temporary and do not require impairment charges.
- Japan Sales Trends: Monitor the recovery of Aflac Japan's medical product sales, which declined 16.3% year-to-date, and the impact of the new "WAYS" product on ordinary life sales.
- Interest Rate Sensitivity: Assess the impact of continued rising interest rates on the fair value of the $48.4 billion debt portfolio and the potential for future unrealized losses.
- Debt Maturities: Confirm the schedule for remaining Samurai notes and the $450 million senior notes due in 2009.
- Share Repurchases: Track the execution of the share repurchase program, with approximately 43 million shares remaining available for purchase as of June 30, 2006.